Abstract:Exosome therapy has garnered significant attention due to its natural delivery capabilities, low toxicity, high biocompatibility, and potential for personalised treatment through engineering modifications. Recent studies have highlighted the ability of tumour cell-derived exosomes (TDEs) to interact with immune cells or modify the immune microenvironment to suppress host immune responses, as well as their unique homing ability to parental cells. The core question of this study is whether this immunomodulatory property of TDEs can be utilised for the immunotherapy of inflammatory diseases. In our experiments, we prepared exosomes derived from murine colon cancer cells CT26 (CT26 exo) using ultracentrifugation, characterised them, and conducted proteomic analysis. The therapeutic potential of CT26 exo was evaluated in our dextran sulphate sodium salt (DSS)-induced inflammatory bowel disease (IBD) mouse model. Compared to the control and 293 T exo treatment groups, mice treated with CT26 exo showed a reduction in the disease activity index (DAI) and colon shortening rate, with no noticeable weight loss. Haematoxylin and eosin (H&E) staining of colon paraffin sections revealed reduced inflammatory infiltration and increased epithelial goblet cells in the colons of CT26 exo-treated group. Furthermore, we conducted preliminary mechanistic explorations by examining the phenotyping and function of CD4+ T cells and dendritic cells (DCs) in the colonic lamina propria of mice. The results indicated that the ameliorative effect of CT26 exosomes might be due to their inhibition of pro-inflammatory cytokine secretion by colonic DCs and selective suppression of Th17 cell differentiation in the colon. Additionally, CT26 exo exhibited good biosafety. Our findings propose a novel exosome-based therapeutic approach for IBD and suggest the potential application of TDEs in the treatment of inflammatory diseases.

Plant-Derived Exosomes as a Drug-Delivery Approach for the Treatment of Inflammatory Bowel Disease and Colitis-Associated Cancer

Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far?

Exosomes as a New Delivery Vehicle in Inflammatory Bowel Disease

Exosome-mediated Effects and Applications in Inflammatory Bowel Disease

Exosome-Induced Regulation in Inflammatory Bowel Disease

Mesenchymal Stem Cell-derived Exosomes: Novel Therapeutic Approach for Inflammatory Bowel Diseases

Anti-cytokine Therapy and Small Molecule Agents for the Treatment of Inflammatory Bowel Disease

Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease

Exosomes derived from cancer cells relieve inflammatory bowel disease in mice

Site-specific Targeted Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease.

Extracellular Vesicles: The Next Generation Theranostic Nanomedicine for Inflammatory Bowel Disease

Medicinal plant-based drug delivery system for inflammatory bowel disease

[Research progress of mesenchymal stem cell-derived exosomes in the treatment of inflammatory bowel disease].

Extracellular Vesicles: A New Nano Tool for the Treatment of Inflammatory Bowel Diseases

Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease.

Advances in the Therapeutic Applications of Plant-Derived Exosomes in the Treatment of Inflammatory Diseases

Systematic Exposition of Mesenchymal Stem Cell for Inflammatory Bowel Disease and Its Associated Colorectal Cancer

Intestinal organoids and organoids extracellular vesicles for inflammatory bowel disease treatment

Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies

Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease

Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases